Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Medline’s $6.26B Nasdaq debut turns a PE-era debt story into a public market test

Medline’s $6.26B Nasdaq debut turns a PE-era debt story into a public market test

Money Moves

A blowout first-day pop and a fully exercised greenshoe push MDLN into its next phase: debt paydown execution under daily price discovery.

December 18th, 2025: IPO closes; underwriters fully exercise greenshoe, lifting deal to ~248.4M shares

Overview

Medline's Nasdaq arrival as MDLN quickly turned from “biggest IPO of 2025” into a live market verdict. Shares jumped roughly 41% in their first session, pushing the company into a roughly $50B+ valuation almost immediately.

Then came the mechanical but meaningful follow-through—its IPO officially closed on December 18, with underwriters fully exercising the 30-day option for extra shares. That boosts the total deal size and accelerates the capital-structure cleanup. 2026 is the real test: how fast leverage comes down, how tariffs flow through margins, and how long public investors stay patient with a PE-era balance sheet.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

$7.2B
Gross proceeds raised (incl. greenshoe)
Total gross proceeds after IPO closing and full exercise of the underwriters’ option.
248,439,654
Total shares sold (incl. greenshoe)
Final share count sold in the IPO after the option was fully exercised.
32,405,172
Underwriters’ option (greenshoe) shares
Additional shares purchased via full exercise of the underwriters’ option at the IPO price.
~+41% (to ~$41)
First-day move vs. IPO price
MDLN’s first-session surge strengthened the “PE exit window re-opens” narrative.
$16.8B → $12.8B
Targeted debt reduction
IPO proceeds were positioned primarily to repay senior secured term-loan debt (core deleveraging goal remains central).
$150M–$200M
Estimated 2026 tariff hit (pre-tax)
Management flagged tariffs as a meaningful earnings headwind.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 3 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

June 2021 December 2025

8 events Latest: December 18th, 2025 · 6 months ago
Tap a bar to jump to that date
  1. IPO closes; underwriters fully exercise greenshoe, lifting deal to ~248.4M shares

    Latest IPO

    Medline closed its IPO at $29/share and said underwriters fully exercised the option for additional shares, bringing total shares sold to 248,439,654 and gross proceeds to about $7.2B.

  2. MDLN starts trading

    Market

    Medline begins trading on the Nasdaq Global Select Market under ticker MDLN.

  3. MDLN surges about 41% in first session, sharpening the ‘public-market test’

    Market

    Medline shares jumped roughly 41% from the $29 IPO price in their first session, signaling strong demand and immediately raising the stakes for follow-through on deleveraging.

  4. Pricing night: upsized at $29

    IPO

    Medline prices 216,034,482 shares at $29 and sets MDLN trading for Dec. 17.

  5. Medline files in public

    Filing

    Medline publicly files its S-1 and targets Nasdaq ticker MDLN.

  6. The IPO quietly starts

    Filing

    Medline confidentially submits a draft S-1 to the SEC for a proposed IPO.

  7. Succession plan goes public

    Leadership

    Medline names Jim Boyle CEO, with leadership transition effective October 1, 2023.

  8. Private equity strikes the deal

    Deal

    Blackstone, Carlyle, and Hellman & Friedman agree to a majority Medline investment.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2015

First Data IPO (KKR-backed)

KKR brought payments processor First Data public after a leveraged buyout and years of debt overhang. The IPO was framed as a step toward reducing leverage and restoring flexibility.

Then

The company gained access to public capital and visibility, but debt remained central.

Now

First Data ultimately exited via a strategic deal, showing IPOs can be a waypoint.

Why this matters now

Medline’s IPO similarly reads as a deleveraging-and-liquidity bridge, not an endpoint.

2020

Albertsons IPO (Cerberus-led ownership)

Grocery chain Albertsons returned to public markets while still heavily sponsor-influenced. The listing created a tradable vehicle, but ownership and exit timing stayed staged over years.

Then

Public investors priced steady cash flows alongside leverage and competitive pressures.

Now

Sponsors’ liquidity path depended on market windows and follow-on transactions.

Why this matters now

Medline’s owners face the same reality: exits happen in chapters, not one night.

2013–2018

Dell’s Return to Public Markets

Dell went private in a leveraged deal, then engineered a route back to public markets to regain flexibility and reshape its capital story.

Then

The structure reduced constraints and broadened the investor base.

Now

The market ultimately judged execution and cash flow more than the comeback narrative.

Why this matters now

Medline’s ‘public again’ moment will matter less than post-IPO execution under scrutiny.

Sources

(15)